| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 493.74 | 310.84 | 216.08 | 162.65 | 233.21 |
Total Income | 13,458.26 | 12,978.42 | 11,815.34 | 10,796.84 | 9,098.22 |
Total Expenditure | 10,452.37 | 10,543.58 | 10,092.79 | 8,596.23 | 6,922.62 |
PBIDT | 3,005.89 | 2,434.84 | 1,722.55 | 2,200.61 | 2,175.6 |
Interest | 121.7 | 112.41 | 107.36 | 52.37 | 58.92 |
PBDT | 2,884.19 | 2,322.43 | 1,615.19 | 2,148.24 | 2,116.68 |
Depreciation | 357.16 | 299.3 | 310.42 | 303.96 | 274.58 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 523.6 | 422.28 | 273.9 | 361.98 | 396.53 |
Deferred Tax | -212.57 | -210.61 | 24.06 | -198.02 | -172.2 |
Reported Profit After Tax | 2,216 | 1,811.46 | 1,006.81 | 1,680.32 | 1,617.77 |
Minority Interest After NP | 49.9 | 15.69 | 22.64 | 34.7 | 32.75 |
Net Profit after Minority Interest | 2,165.48 | 1,795.77 | 984.17 | 1,645.62 | 1,585.02 |
Extra-ordinary Items | 0 | -96.13 | -79.46 | -12.02 | 0 |
Adjusted Profit After Extra-ordinary item | 2,165.48 | 1,891.9 | 1,063.63 | 1,657.64 | 1,585.02 |
EPS (Unit Curr.) | 181.11 | 150.19 | 82.31 | 137.63 | 132.57 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 2,250 | 2,000 | 3,450 | 1,700 | 1,500 |
Equity | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 23.18 | 19.22 | 14.85 | 20.69 | 24.54 |
PBDTM(%) | 22.24 | 18.33 | 13.92 | 20.2 | 23.87 |
PATM(%) | 17.09 | 14.29 | 8.67 | 15.8 | 18.24 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
